Palvella Therapeutics (NASDAQ:PVLA) is preparing for a potential commercial launch of QTORIN rapamycin while advancing additional rare skin and vascular anomaly programs, Chief Financial Officer Matt ...
An immune drug from Roivant could be headed to a new market, after the company reported positive trials in the eye disease ...
CIARA Burnside gave birth to son Ralph but something was immediately wrong – inside her womb the helpless baby’s skin had ...
Symptoms are often mistaken for irritation, thrush or an STI, delaying proper treatment. Campaigners say the taboo around ...
Shortly after winning a clearance in the skin disease dermatomyositis, brepocitinib posted results suggesting it might also ...
Everyday Health on MSN
15 conditions commonly mistaken for multiple sclerosis
People with MS are commonly misdiagnosed with other medical conditions, and the reverse is also true. Learn which ...
Research shows both disease types may arise from shared inflammatory pathways, genetic susceptibilities, and potential ...
Months after the FDA rejected its treatment for a rare light-sensitivity disease, the biotech claimed success in a Phase 3 ...
Brepocitinib is on a roll. After winning approval for an autoimmune skin disease, Roivant Sciences subsidiary Priovant’s drug ...
A lump in the breast is the most commonly known symptom of breast cancer, but the signs go beyond that. Experts share ...
A case report describes a 14-year-old boy whose common cold virus triggered atypical hemolytic uremic syndrome with severe skin necrosis that required surgical debridement after drug therapy failed.
Disc Medicine’s bitopertin—rejected by the FDA in February—significantly reduced levels of a key disease biomarker and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results